CytomX Therapeutics Cash on Hand 2014-2022 | CTMX

CytomX Therapeutics cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
CytomX Therapeutics Annual Cash on Hand
(Millions of US $)
2021 $305
2020 $316
2019 $296
2018 $436
2017 $374
2016 $182
2015 $187
2014 $64
2013 $9
CytomX Therapeutics Quarterly Cash on Hand
(Millions of US $)
2022-09-30 $194
2022-06-30 $228
2022-03-31 $263
2021-12-31 $305
2021-09-30 $236
2021-06-30 $266
2021-03-31 $394
2020-12-31 $316
2020-09-30 $321
2020-06-30 $346
2020-03-31 $248
2019-12-31 $296
2019-09-30 $326
2019-06-30 $349
2019-03-31 $397
2018-12-31 $436
2018-09-30 $465
2018-06-30 $335
2018-03-31 $361
2017-12-31 $374
2017-09-30 $331
2017-06-30 $336
2017-03-31 $163
2016-12-31 $182
2016-09-30 $178
2016-06-30 $196
2016-03-31 $181
2015-12-31 $187
2015-09-30 $114
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2013-12-31 $9
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.122B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.298B 9.44
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.439B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.570B 0.00
Arcus Biosciences (RCUS) United States $1.208B 0.00
Biohaven (BHVN) United States $0.950B 0.00
Emergent Biosolutions (EBS) United States $0.405B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.161B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00
Gelesis Holdings (GLS) United States $0.015B 0.00